Blueprint Medicines (BPMC) Tops Q1 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Barclays Starts Blueprint Medicines (BPMC) at Equalweight
May 4, 2020 5:31 PM EDTBarclays analyst Peter Lawson initiates coverage on Blueprint Medicines (NASDAQ: BPMC) with a Equalweight rating and a price target of $59.00.
For an analyst ratings summary and ratings history on Blueprint Medicines click here. For more ratings news on Blueprint Medicines click here.
Shares of Blueprint Medicines closed at $57.15 yesterday.
... More